Clinical and Economic Outcomes of Intravenous Brivaracetam Compared With Levetiracetam for the Treatment of Seizures in United States Hospitals.

Beaty, Silky; Rosenthal, Ning A; Gayle, Julie; Dongre, Prashant; Ricchetti-Masterson, Kristen

Beaty, Silky; Rosenthal, Ning A; Gayle, Julie; Dongre, Prashant; Ricchetti-Masterson, Kristen.

Afiliación

Beaty S; UCB Pharma, Smyrna, GA, United States.
Rosenthal NA; Premier Applied Sciences, Premier Inc., Charlotte, NC, United States.
Gayle J; Premier Applied Sciences, Premier Inc., Charlotte, NC, United States.
Dongre P; UCB Pharma, Smyrna, GA, United States.
Ricchetti-Masterson K; UCB Pharma, Raleigh, NC, United States.

Front Neurol ; 12: 760855, 2021.

Article en En | MEDLINE | ID: mdl-34912285

Palabras clave

SV2A ligand; cost; effectiveness; hospital; intravenous antiseizure medication; seizure

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Observational_studies / Risk_factors_studies Idioma: En Revista: Front Neurol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google